648 related articles for article (PubMed ID: 21642543)
1. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
2. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
[TBL] [Abstract][Full Text] [Related]
3. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
[TBL] [Abstract][Full Text] [Related]
4. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.
Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT
FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600
[TBL] [Abstract][Full Text] [Related]
5. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
Ståhl AL; Sartz L; Karpman D
Blood; 2011 May; 117(20):5503-13. PubMed ID: 21447825
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
[TBL] [Abstract][Full Text] [Related]
7. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
Zoja C; Buelli S; Morigi M
Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442
[TBL] [Abstract][Full Text] [Related]
8. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
10. Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome.
Buelli S; Locatelli M; Carminati CE; Corna D; Cerullo D; Imberti B; Perico L; Brigotti M; Abbate M; Zoja C; Benigni A; Remuzzi G; Morigi M
Cells; 2022 May; 11(11):. PubMed ID: 35681450
[TBL] [Abstract][Full Text] [Related]
11. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
[TBL] [Abstract][Full Text] [Related]
12. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.
Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL
Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476
[TBL] [Abstract][Full Text] [Related]
13. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA
Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697
[TBL] [Abstract][Full Text] [Related]
14. Complement in typical hemolytic uremic syndrome.
Orth D; Würzner R
Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
[TBL] [Abstract][Full Text] [Related]
15. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
[TBL] [Abstract][Full Text] [Related]
16. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1.
Zoja C; Angioletti S; Donadelli R; Zanchi C; Tomasoni S; Binda E; Imberti B; te Loo M; Monnens L; Remuzzi G; Morigi M
Kidney Int; 2002 Sep; 62(3):846-56. PubMed ID: 12164866
[TBL] [Abstract][Full Text] [Related]
17. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
Louise CB; Obrig TG
Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301
[TBL] [Abstract][Full Text] [Related]
18. Platelet thrombus formation in eHUS is prevented by anti-MBL2.
Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF
PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024
[TBL] [Abstract][Full Text] [Related]
19. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.
Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J
J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701
[TBL] [Abstract][Full Text] [Related]
20. Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
Orth-Höller D; Würzner R
Semin Thromb Hemost; 2014 Jun; 40(4):503-7. PubMed ID: 24799304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
